Ardelyx, Inc., a specialized biopharmaceutical company, develops and sells disruptive medicines for the treatment of cardio renal and gastrointestinal diseases in the United States and Asia Pacific. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program for the treatment of patients with hyperkalemia; RDX8940, an oral TGR5 agonist; RDX011, a NHE3 inhibitor; and RDX023 program for the development of gut-biased farnesoid X receptor agonists. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ARDX
CUSIPN/A
Phone510-745-1700
Debt
Debt-to-Equity RatioN/A
Current Ratio10.28
Quick Ratio10.28
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$42 million
Price / Sales4.99
Cash FlowN/A
Price / CashN/A
Book Value$2.93 per share
Price / Book1.50
Profitability
EPS (Most Recent Fiscal Year)($1.36)
Net Income$-64,330,000.00
Net MarginsN/A
Return on Equity-39.53%
Return on Assets-35.10%
Miscellaneous
Employees75
Outstanding Shares47,600,000
Market Cap$209.46
Ardelyx (NASDAQ:ARDX) Frequently Asked Questions
What is Ardelyx's stock symbol?
Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."
How were Ardelyx's earnings last quarter?
Ardelyx Inc (NASDAQ:ARDX) released its earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.36) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.46) by $0.10. The biopharmaceutical company had revenue of $2.32 million for the quarter. View Ardelyx's Earnings History.
What price target have analysts set for ARDX?
5 brokerages have issued twelve-month price targets for Ardelyx's stock. Their predictions range from $12.00 to $17.00. On average, they anticipate Ardelyx's stock price to reach $14.00 in the next twelve months. This suggests a possible upside of 218.2% from the stock's current price. View Analyst Ratings for Ardelyx.
What is the consensus analysts' recommendation for Ardelyx?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Are investors shorting Ardelyx?
Ardelyx saw a decrease in short interest in June. As of June 15th, there was short interest totalling 366,068 shares, a decrease of 36.9% from the May 31st total of 580,042 shares. Based on an average daily volume of 754,632 shares, the short-interest ratio is presently 0.5 days. Currently, 0.9% of the company's stock are sold short. View Ardelyx's Current Options Chain.
Who are some of Ardelyx's key competitors?
Some companies that are related to Ardelyx include ANI Pharmaceuticals Inc Common Stock (ANIP), Amarin (AMRN), Homology Medicines (FIXX), Rocket Pharmaceuticals (RCKT), Amphastar Pharmaceuticals (AMPH), Kiniksa Pharmaceuticals (KNSA), Eidos Therapeutics (EIDX), Inflarx (IFRX), AMAG Pharmaceuticals (AMAG), NuCana (NCNA), Adamas Pharmaceuticals (ADMS), CymaBay Therapeutics (CBAY), GlycoMimetics (GLYC), Dova Pharmaceuticals (DOVA) and Abeona Therapeutics (ABEO).
Who are Ardelyx's key executives?
Ardelyx's management team includes the folowing people:
- Mr. Michael G. Raab, Pres, CEO & Director (Age 53)
- Dr. Reginald Seeto, COO & Exec. VP (Age 46)
- Dr. Paul Korner, Chief Medical Officer & Exec. VP (Age 52)
- Mr. Mark E. Kaufmann MBA, CFO & Treasurer (Age 50)
- Mr. Bryan Shaw, Chief Accounting Officer, VP and Controller (Age 64)
Has Ardelyx been receiving favorable news coverage?
Media coverage about ARDX stock has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Ardelyx earned a media sentiment score of 0.15 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 45.89 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
Who are Ardelyx's major shareholders?
Ardelyx's stock is owned by many different of institutional and retail investors. Top institutional shareholders include NEW ENTERPRISE ASSOCIATES 12, LIMITED PARTNERSHIP Total Shares: 16,736,044 (27.20%) and NEW ENTERPRISE ASSOCIATES 12, LIMITED PARTNERSHIPTotal Shares:16,736,044 (27.20%). Company insiders that own Ardelyx stock include David P Rosenbaum, Elizabeth A Grammer, Forest Baskett, Gordon Ringold, Jeffrey W Jacobs, Jeremy S Caldwell and Reginald Seeto. View Institutional Ownership Trends for Ardelyx.
How do I buy shares of Ardelyx?
Shares of ARDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ardelyx's stock price today?
One share of ARDX stock can currently be purchased for approximately $4.40.
How big of a company is Ardelyx?
Ardelyx has a market capitalization of $209.46 million and generates $42 million in revenue each year. The biopharmaceutical company earns $-64,330,000.00 in net income (profit) each year or ($1.36) on an earnings per share basis. Ardelyx employs 75 workers across the globe.
How can I contact Ardelyx?
Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The biopharmaceutical company can be reached via phone at 510-745-1700 or via email at [email protected]
MarketBeat Community Rating for Ardelyx (NASDAQ ARDX)
MarketBeat's community ratings are surveys of what our community members think about Ardelyx and other stocks. Vote "Outperform" if you believe ARDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
